SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment shares are trading higher as investors react to a strong quarterly earnings report featuring a revenue beat and a record funded backlog, alongside significant contract wins for its high-energy laser weapon systems. While some retail traders are debating the company's valuation and the potential for federal budget timing to impact future growth, the overall sentiment remains optimistic regarding the company's long-term defense and drone technology positioning.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Compass Pathways is trending following positive 52-week clinical trial data for its COMP360 psilocybin treatment, which showed durable reduction in depression severity and potential for a 2027 commercial launch. Investors are reacting positively to the durability results and upcoming management presentations at healthcare conferences, though some discussion remains focused on long-term commercialization logistics and resistance levels around the $15 price point.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera is trending following positive clinical data for its ABCL635 treatment and subsequent significant insider buying, which has fueled investor optimism despite concerns from bears regarding the company's valuation, dilution, and timeline for commercialization. The conversation is dominated by bullish sentiment regarding the company's long-term platform value, with many participants monitoring for potential short squeezes and further partnership updates.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and the community react to a recent campaign promise by Donald Trump to issue a $5,000 dividend to every adult citizen if Republicans retain control of Congress. Discussion is heavily polarized, with critics labeling the proposal as an irresponsible, inflation-fueling bribe, while supporters view it as a demonstration of economic strength.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta shares are rising following the launch of Muse, an autonomous personal AI assistant capable of performing multi-step tasks across apps. While many traders are optimistic about the tool's monetization potential, some remain skeptical regarding its long-term impact on revenue and ongoing infrastructure spending.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

The community is discussing a significant $1 billion strategic minority investment in the company by the Abu Dhabi sovereign wealth fund, Mubadala Investment. Traders are optimistic that this institutional backing, combined with an upsized share repurchase program, signals strong long-term value and bolsters the case for a future stock relisting.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

The primary catalyst for movement is the company's product launch event featuring the new 'iPhone Duo' foldable device and updated iPhone 18 Pro series, which has sparked intense debate among traders regarding its high price point and the firm's level of innovation. While bullish traders view the new hardware as a status symbol that could unlock significant revenue, many observers remain skeptical, with some comparing it to earlier product launches and others questioning the market's reception.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is facing downward pressure following the release of Phase 3 IZAR-1 trial results in psoriatic arthritis, which met endpoints but failed to demonstrate clear superiority over competitors. Investors are reacting to the clinical data, the filing of a mixed shelf offering, and frustration with the company's communication and strategy regarding commercialization versus a potential buyout.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

The conversation is dominated by speculation regarding a potential buyout, fueled by unverified market rumors and the company's strong commercial performance with its MS drug, Briumvi. While some traders debate the likelihood and potential valuation of an acquisition, others argue that the company's long-term growth prospects as an independent entity remain the primary value driver.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

Troll is receiving attention from traders who view it as a high-potential "OG" meme coin with unique IP rights, leading to frequent community-led campaigns to drive its adoption and valuation. The conversation is dominated by bullish sentiment from advocates comparing the token's potential to other major meme coins and historical market phenomena.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

WED 8/26: $DBX – BUYING (1/3) @ $35.10 
 
10:04 AM – Picking up a 1/3 position in this Computer Software-Database stock as shares trade higher from the 10 DMA while volume is currently running 38% above average. That combination of support at the 10 DMA, advancing price, and increased volume gives me a technical BUY SIGNAL. 
 
James’ Trader’s Tip: Volume Helps Confirm Support 
  • An advance from the 10 DMA shows that buyers are defending an important short-term support level. 
  • Above-average volume adds conviction to the move by showing stronger-than-normal demand. 
  • When price and volume improve together, the technical setup becomes more compelling. 
https://buyingbreakouts.com/wed-8-26-dbx-buying-1-3-35-10/

10:04 AM - Picking up a 1/3 position in this Computer Software-Database stock as shares trade higher from the 10 DMA while volume is currently running 38% above average. That combination of support at the 10 DMA, advancing price, and increased volume gives me a technical BUY SIGNAL.

Buyingbreakouts

WED 8/26: DBX - BUYING (1/3) @ $35.10

StockTwits Web

Dropbox Inc

 – BUYING (1/3) @ $35.10 
 
10:04 AM – Picking up a 1/3 position in this Computer Software-Database stock as shares trade higher from the 10 DMA while volume is currently running 38% above average. That combination of support at the 10 DMA, advancing price, and increased volume gives me a technical BUY SIGNAL. 
 
James’ Trader’s Tip: Volume Helps Confirm Support 
  • An advance from the 10 DMA shows that buyers are defending an important short-term support level. 
  • Above-average volume adds conviction to the move by showing stronger-than-normal demand. 
  • When price and volume improve together, the technical setup becomes more compelling. 
